Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Brief Summary: The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.


Options:
A: Arm Label: AN2728 Topical Ointment, 2%; Type: EXPERIMENTAL; Interventions: Drug: AN2728 Topical Ointment, 2% | Arm Label: Matching vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching vehicle control | Intervention Type: DRUG; Name: AN2728 Topical Ointment, 2%; Assigned to Arm(s): AN2728 Topical Ointment, 2% | Intervention Type: DRUG; Name: Matching vehicle control; Assigned to Arm(s): Matching vehicle control
B: Arm Label: Vehicle Control (VC) Period: Vehicle Cream BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle cream | Arm Label: VC Period: Ruxolitinib 0.75% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: VC Period: Ruxolitinib 1.5% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: LTS Period: Ruxolitinib 0.75% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: LTS Period: Ruxolitinib 1.5% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Intervention Type: DRUG; Name: Ruxolitinib cream; Assigned to Arm(s): LTS Period: Ruxolitinib 0.75% Cream BID, LTS Period: Ruxolitinib 1.5% Cream BID, LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID, Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID, VC Period: Ruxolitinib 0.75% Cream BID, VC Period: Ruxolitinib 1.5% Cream BID | Intervention Type: DRUG; Name: Vehicle cream; Assigned to Arm(s): Vehicle Control (VC) Period: Vehicle Cream BID
C: Arm Label: Betamethasone-17-valerat + placebo ointment; Type: EXPERIMENTAL; Interventions: Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo | Arm Label: Tacrolimus ointment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Protopic, tacrolimus ointment 0.1% | Intervention Type: DRUG; Name: Betnovate, betamethasone dipropionate ointment 0.1% and placebo; Assigned to Arm(s): Betamethasone-17-valerat + placebo ointment | Intervention Type: DRUG; Name: Protopic, tacrolimus ointment 0.1%; Assigned to Arm(s): Tacrolimus ointment
D: Arm Label: Roflumilast Cream 0.05%; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast Cream 0.05% | Arm Label: Roflumilast Cream 0.15%; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast Cream 0.15% | Arm Label: Vehicle Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle Cream | Intervention Type: DRUG; Name: Roflumilast Cream 0.05%; Assigned to Arm(s): Roflumilast Cream 0.05% | Intervention Type: DRUG; Name: Roflumilast Cream 0.15%; Assigned to Arm(s): Roflumilast Cream 0.15% | Intervention Type: DRUG; Name: Vehicle Cream; Assigned to Arm(s): Vehicle Cream

Answer: A